BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35373866)

  • 21. Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area.
    Alfieri S; Iacovelli NA; Marceglia S; Lasorsa I; Resteghini C; Taverna F; Mazzocchi A; Orlandi E; Guzzo M; Bianchi R; Fanti D; Pala L; Racca S; Dvir R; Quattrone P; Gloghini A; Volpi CC; Granata R; Bergamini C; Locati L; Licitra L; Bossi P
    Oncotarget; 2017 Jul; 8(29):47780-47789. PubMed ID: 28562354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spontaneous remission of residual post-therapy plasma Epstein-Barr virus DNA and its prognostic implication in nasopharyngeal carcinoma: A large-scale, big-data intelligence platform-based analysis.
    Zhang Y; Tang LL; Li YQ; Liu X; Liu Q; Ma J
    Int J Cancer; 2019 May; 144(9):2313-2319. PubMed ID: 30485420
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical characteristics and prognostic value of pre-retreatment plasma epstein-barr virus DNA in locoregional recurrent nasopharyngeal carcinoma.
    Liu MZ; Fang SG; Huang W; Wang HY; Tian YM; Huang RD; Sun Z; Zhao C; Lu TX; Huang Y; Han F
    Cancer Med; 2019 Aug; 8(10):4633-4643. PubMed ID: 31268626
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of serum Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein-Barr virus DNA.
    Yao JJ; Lin L; Jin YN; Wang SY; Zhang WJ; Zhang F; Zhou GQ; Cheng ZB; Qi ZY; Sun Y
    Cancer Sci; 2017 Aug; 108(8):1640-1647. PubMed ID: 28603915
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Maximal standard uptake values of
    Sun XS; Liang YJ; Liu SL; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Tang LQ; Mai HQ
    BMC Cancer; 2019 Sep; 19(1):908. PubMed ID: 31511059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of Epstein-Barr virus DNA load in nasopharyngeal carcinoma: a meta-analysis.
    Alami IE; Gihbid A; Charoute H; Khaali W; Brahim SM; Tawfiq N; Cadi R; Belghmi K; El Mzibri M; Khyatti M
    Pan Afr Med J; 2022; 41():6. PubMed ID: 35145598
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison between the seventh and eighth edition of the AJCC/UICC staging system for nasopharyngeal cancer integrated with pretreatment plasma Epstein-Barr virus DNA level in a non-Chinese population: secondary analysis from a prospective randomized trial.
    Kitpanit S; Jittapiromsak N; Sriyook A; Prayongrat A; Kannarunimit D; Chakkabat C; Lertbutsayanukul C
    Jpn J Clin Oncol; 2019 Dec; 49(12):1100-1113. PubMed ID: 31334768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of plasma Epstein-Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy.
    Li WF; Zhang Y; Huang XB; Du XJ; Tang LL; Chen L; Peng H; Guo R; Sun Y; Ma J
    Chin J Cancer; 2017 Nov; 36(1):87. PubMed ID: 29116021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of a novel model incorporating serological indicators into the conventional TNM staging system for nasopharyngeal carcinoma.
    Ding C; Dai DY; Luo ZK; Wang GY; Dong Z; Qin GJ; Du XJ; Ma J
    Oral Oncol; 2024 Apr; 151():106725. PubMed ID: 38430711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identifying optimal candidates for local treatment of the primary tumor among patients with de novo metastatic nasopharyngeal carcinoma: a retrospective cohort study based on Epstein-Barr virus DNA level and tumor response to palliative chemotherapy.
    Sun XS; Liu LT; Liu SL; Guo SS; Wen YF; Xie HJ; Tang QN; Liang YJ; Li XY; Yan JJ; Ma J; Chen QY; Tang LQ; Mai HQ
    BMC Cancer; 2019 Jan; 19(1):92. PubMed ID: 30665378
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantification of Epstein-Barr virus DNA load in nasopharyngeal brushing samples in the diagnosis of nasopharyngeal carcinoma in southern China.
    Zheng XH; Lu LX; Li XZ; Jia WH
    Cancer Sci; 2015 Sep; 106(9):1196-201. PubMed ID: 26082292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical implications of hepatitis B viral infection in Epstein-Barr virus-associated nasopharyngeal carcinoma.
    Xu T; Huang Z; Deng Y; Wang S; Su B; Wei W; Wang D; Jiang J; Li A; Zhang G; Yang H; Claret FX; Hu W
    J Clin Virol; 2015 Mar; 64():64-71. PubMed ID: 25728081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epstein-Barr virus DNA load in nasopharyngeal brushings and whole blood in nasopharyngeal carcinoma patients before and after treatment.
    Adham M; Greijer AE; Verkuijlen SA; Juwana H; Fleig S; Rachmadi L; Malik O; Kurniawan AN; Roezin A; Gondhowiardjo S; Atmakusumah D; Stevens SJ; Hermani B; Tan IB; Middeldorp JM
    Clin Cancer Res; 2013 Apr; 19(8):2175-86. PubMed ID: 23493345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combining pretreatment plasma Epstein-Barr virus DNA level and cervical node necrosis improves prognostic stratification in patients with nasopharyngeal carcinoma: A cohort study.
    Du YY; Luo DH; Sun XS; Tang LQ; Mai HQ; Chen QY; Zhong JH; Mai DM; Zhang WR; Chen WH; Mo HY
    Cancer Med; 2019 Nov; 8(16):6841-6852. PubMed ID: 31513364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel prognostic model predicts overall survival in patients with nasopharyngeal carcinoma based on clinical features and blood biomarkers.
    Lai C; Zhang C; Lv H; Huang H; Ke X; Zhou C; Chen H; Chen S; Zhou L
    Cancer Med; 2021 Jun; 10(11):3511-3523. PubMed ID: 33973727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proposed prognostic subgroups and facilitated clinical decision-making for additional locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: a retrospective study based on recursive partitioning analysis.
    Yao Y; Sun X; Huang H; Wang Z; Fang X; Chen M; Chen Z; Weng H; Guo C; Hong H; Huang H; Lin T
    Radiat Oncol; 2023 Jan; 18(1):15. PubMed ID: 36681832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combining plasma Epstein-Barr virus DNA and nodal maximal standard uptake values of 18F-fluoro-2-deoxy-D-glucose positron emission tomography improved prognostic stratification to predict distant metastasis for locoregionally advanced nasopharyngeal carcinoma.
    Chen WH; Tang LQ; Zhang L; Chen QY; Guo SS; Liu LT; Fan W; Zhang X; Guo L; Zhao C; Cao KJ; Qian CN; Guo X; Xie D; Zeng MS; Mai HQ
    Oncotarget; 2015 Nov; 6(35):38296-307. PubMed ID: 26512922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clinical utility of plasma Epstein-Barr virus DNA assays in nasopharyngeal carcinoma: the dawn of a new era?: a systematic review and meta-analysis of 7836 cases.
    Zhang W; Chen Y; Chen L; Guo R; Zhou G; Tang L; Mao Y; Li W; Liu X; Du X; Sun Y; Ma J
    Medicine (Baltimore); 2015 May; 94(20):e845. PubMed ID: 25997061
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epstein-Barr Virus DNA in Nasopharyngeal Carcinoma: A Brief Review.
    Xue F; He X
    Methods Mol Biol; 2020; 2204():99-107. PubMed ID: 32710318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective study of prognostic value of Raf kinase inhibitory protein and pretreatment plasma Epstein-Barr virus DNA for distant metastasis in locoregionally advanced nasopharyngeal carcinoma.
    Li SW; Wang H; Xiang YQ; Zhang HB; Lv X; Xia WX; Zeng MS; Mai HQ; Hong MH; Guo X
    Head Neck; 2013 Apr; 35(4):579-91. PubMed ID: 22605662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.